Form 8-K - Current report:
SEC Accession No. 0001214659-25-010209
Filing Date
2025-07-09
Accepted
2025-07-09 16:30:40
Documents
16
Period of Report
2025-07-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 i792518k.htm   iXBRL 8-K 25219
2 EXHIBIT 3.1 ex3_1.htm EX-3.1 8080
6 GRAPHIC ex31-001.jpg GRAPHIC 52737
7 GRAPHIC ex31-002.jpg GRAPHIC 196456
8 GRAPHIC ex31-003.jpg GRAPHIC 44872
  Complete submission text file 0001214659-25-010209.txt   611966

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE alzn-20250709.xsd EX-101.SCH 2990
4 XBRL LABEL FILE alzn-20250709_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE alzn-20250709_pre.xml EX-101.PRE 22342
18 EXTRACTED XBRL INSTANCE DOCUMENT i792518k_htm.xml XML 4031
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 251113923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)